Authors
Latest:
Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future DirectionsIn Part 2 of this review article, we discuss the management of primary CNS lymphoma, focusing in particular on systemic therapies and radiation, as well as provide clinicians with a comprehensive overview by covering the key investigations that have brought us to our current state of knowledge, and studies that may guide future interventions.
Latest:
Improving Childhood Cancer Survivor Care Through Web-Based PlatformsHere, we review the barriers to adherence, including those unique to childhood cancer survivors, and the rationale for distribution of a survivorship care plan. We also discuss advantages and potential limitations of delivering survivorship care plans via web-based platforms, and describe the unique features of one of these platforms, Passport for Care.
Latest:
Improving Childhood Cancer Survivor Care Through Web-Based PlatformsHere, we review the barriers to adherence, including those unique to childhood cancer survivors, and the rationale for distribution of a survivorship care plan. We also discuss advantages and potential limitations of delivering survivorship care plans via web-based platforms, and describe the unique features of one of these platforms, Passport for Care.
Latest:
Improving Childhood Cancer Survivor Care Through Web-Based PlatformsHere, we review the barriers to adherence, including those unique to childhood cancer survivors, and the rationale for distribution of a survivorship care plan. We also discuss advantages and potential limitations of delivering survivorship care plans via web-based platforms, and describe the unique features of one of these platforms, Passport for Care.
Latest:
Improving Childhood Cancer Survivor Care Through Web-Based PlatformsHere, we review the barriers to adherence, including those unique to childhood cancer survivors, and the rationale for distribution of a survivorship care plan. We also discuss advantages and potential limitations of delivering survivorship care plans via web-based platforms, and describe the unique features of one of these platforms, Passport for Care.
Latest:
Improving Childhood Cancer Survivor Care Through Web-Based PlatformsHere, we review the barriers to adherence, including those unique to childhood cancer survivors, and the rationale for distribution of a survivorship care plan. We also discuss advantages and potential limitations of delivering survivorship care plans via web-based platforms, and describe the unique features of one of these platforms, Passport for Care.
Latest:
Could COX-2 Inhibition With Celecoxib Have Role in Breast Cancer?This video highlights results of REACT, a phase III multi-center double-blind randomized trial of celecoxib vs placebo in patients with breast cancer.
Latest:
Advances in Breast Cancer Screening, DiagnosisThis video highlights recent studies advancing the field of breast cancer screening and diagnosis, including the potential need for increased surveillance in patients with false positives and patient access to mammography.
Latest:
Could Novel Hybrid Imaging Predict Breast Cancer Prognosis?This video highlights a study on optoacoustic imaging, a new type of imaging that could improve breast cancer diagnosis by differentiating between benign and malignant breast masses.
Latest:
Combating Endocrine Resistance in Breast Cancer With Novel Agents, CombinationsThis video reviews endocrine resistance mediated by CDK4/6, FGFR, and PI3K in HR-positive breast cancer, and highlights the latest efforts to inhibit these pathways with novel targeted drugs and combinations.
Latest:
COMPASS: Genomic Profiling Could Guide Treatment in Advanced Pancreatic CancerIn this interview we discuss preliminary results of the COMPASS trial, which used whole-genome sequencing and RNA sequencing to analyze the tumors of patients with advanced pancreatic ductal adenocarcinoma to identify possible first-line treatments.
Latest:
Management of Triple-Negative Breast Cancer in Older Patients: How Is It Different?In this review, we will discuss the role of geriatric assessment, alternative treatment modalities for older women with triple-negative breast cancer, and other special considerations for this patient population.
Latest:
Management of Triple-Negative Breast Cancer in Older Patients: How Is It Different?In this review, we will discuss the role of geriatric assessment, alternative treatment modalities for older women with triple-negative breast cancer, and other special considerations for this patient population.
Latest:
Diffuse Hepatic Infiltration by Metastatic MelanomaMelanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.
Latest:
Is This Patient With Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment?A 67-year-old man, a former smoker, presented with gross hematuria. A CT urogram showed a bladder tumor in the anterior wall and multiple enlarged retroperitoneal lymph nodes. Two vertebral metastases were seen on a bone scan. He underwent a transurethral resection of the bladder, and the pathology report revealed muscle-invasive urothelial carcinoma.
Latest:
Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies-PART 2: Existing Experience and Considerations for Future TrialsIn Part 2 of this two-part series, we review the clinical evidence in support of combining immunotherapy with stereotactic radiosurgery for the treatment of brain metastases; examine controversies regarding radiation dose and fractionation, as well as temporal sequencing of multimodality treatment; and discuss future directions in combined therapy.
Latest:
Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies-PART 2: Existing Experience and Considerations for Future TrialsIn Part 2 of this two-part series, we review the clinical evidence in support of combining immunotherapy with stereotactic radiosurgery for the treatment of brain metastases; examine controversies regarding radiation dose and fractionation, as well as temporal sequencing of multimodality treatment; and discuss future directions in combined therapy.
Latest:
Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of DiseaseDrs. Kato and Kurzrock discuss the potential reasons why some cancer patients experience hyperprogression of disease while on immunotherapy treatment.
Latest:
Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of DiseaseDrs. Kato and Kurzrock discuss the potential reasons why some cancer patients experience hyperprogression of disease while on immunotherapy treatment.
Latest:
Highlights of USPSTF Updates to Prostate Cancer Screening GuidelinesUSPSTF Vice-Chair Alex Krist and prostate cancer specialist David Penson shared perspectives on USPSTF’s updated prostate cancer screening recommendation.
Latest:
Quiz: The Role of CAR T Cells in Multiple MyelomaHow much do you know about the role of CAR T cells in multiple myeloma? Here's your chance to find out.
Latest:
How Does Pre-emptive Plerixafor Affect Stem Cell Mobilization for Myeloma Transplant?A new study suggests there is a cost and efficiency benefit to pre-emptively administrating plerixafor during stem cell collection.
Latest:
Updates on Genetic Testing in Breast CancerIn this video, Dr. Allison Kurian discusses polygenic risk scores, genetic testing in diverse populations, and more as they relate to breast cancer.
Latest:
Managing Adverse Effects in Patients with HER2+ Breast CancerHarold J. Burstein, MD, PhD, discusses the management of adverse events in patients with HER2+ breast cancer, and the Oncology Brothers provide closing thoughts on the entire discussion.
Latest:
A 79-Year-Old Man on Nivolumab with Itchy Erythematous PatchesA 79-year-old white man presented with an ulcerated chest wall lesion developing from an existing mole.
Latest:
E. David Crawford, MD, Reviews Unmet Needs Addressed by FDA Approval of Darolutamide, Docetaxel, and ADT in mHSPCIn an interview with CancerNetwork®, E. David Crawford, MD, discussed implications from the recent FDA approval of darolutamide plus docetaxel and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer based on findings from the phase 3 ARASENS trial.
Latest:
CAR T-Cell Therapy in ALL: Formidible Challenges RemainAt the NCCN Annual Conference, Dr. Bijal Shah of Tampa’s Moffitt Cancer Center highlighted ongoing challenges in administration of CAR T-cell therapy.
Latest:
Treatment Options Expanding in Renal CarcinomaFirst- and second-line treatment of clear cell RCC has changed dramatically, Dr. Eric Jonasch said during the NCCN Annual Conference in Orlando.
Latest:
Response and Development of Immune-Related Adverse Events in an 83-Year-Old Man With Metastatic Urothelial CancerAn 83-year-old man was diagnosed with multiple low-grade transitional cell carcinomas over a 6-year period. A surveillance cystoscopy in year 7 showed high-grade noninvasive papillary urothelial carcinoma in the bladder trigone. A CT urogram showed a soft-tissue mass with diffuse enhancement in the lower pole of the left kidney, concerning for malignancy.
